

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Sixth Wave Innovations Inc. (the "Issuer").

Trading Symbol: SIXW

Number of Outstanding Listed Securities: 80,234,101

Date: September 7, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On August 5, 2020 the Issuer announced that a previously submitted proposal between the Issuer and its partners, York University and the Centre Technologique des Residus Industriels (CTRI) has been approved by the Natural Sciences and Engineering Research Council of Canada (NSERC). The proposal is for the development of the Issuer's AMIPs (accelerated molecularly imprinted polymers) virus detection technology. The project was approved for a start date of Aug. 1, 2020.

The focus of the collaboration is to develop a prototype of the Issuer's AMIP technology to detect viruses in airborne, water and waste water environments, specifically SARS-CoV-2. This collaboration is part of the Issuer's multipronged research and development approach to revolutionize virus detection, by not only testing and monitoring individual patients, but rather alerting entire populations through pro-active virus detection in municipal waste water treatment facilities, or air handling systems (HVAC) in large buildings or indoor facilities. The flexibility of the Issuer's AMIP technology platform could potentially allow for product configuration not possible with traditional testing techniques such as PCR and immunoassay. This flexibility derives from the completely synthetic manufacturing techniques and components of the Issuer's technology resulting in higher stability and significantly less susceptibility to environmental variables such as heat, light and other factors which may impact traditional testing methods.

The Issuer is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 coronavirus) at this time.

Under the scope of the NSERC project the prototype developed by the Issuer and its partners would provide for quantitative virus detection through colorimetric and/or electrochemical signals. These detection systems will be portable, easy to operate and sensitive for future use by inspectors involved in decision-making to address various challenges associated with pathogen outbreaks and pandemics.

If successfully developed, this potential air monitoring application would be able to provide pro-active virus detection capabilities to help maintain confidence in public settings and in the reopening of previously contaminated locations. The application could then potentially be used to provide surveillance and mapping of virus hot spots to help contain further spread.

The project will use non-pathogenic viruses such as bacteriophages and inactivated SARS-CoV-2 for prototype development. Development work on the prototype will be undertaken at York University.

On August 24, 2020 the Issuer announced that it is conducting a non-brokered private placement of up to 10 million units at 30 cents per unit, for total placement proceeds of \$3-million. Each unit consists of one common share and one common share purchase warrant. Each warrant gives the holder the right to purchase one common share of the Issuer at an exercise price of 50 cents for a period of 24 months. The Issuer intends to close the private placement in multiple tranches.

The Issuer plans to use the proceeds of the private placement for the deployment of its Affinity cannabis purification units as well as research into its AMIPs virus-detection technology.

The closing of the private placement is subject to the final approval of the Canadian Securities Exchange.

2. Provide a general overview and discussion of the activities of management.
See item 1 above.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
Not applicable.
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
Not applicable.
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
Not applicable.
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
Not applicable.
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
Not applicable.
8. Describe the acquisition of new customers or loss of customers.
Not applicable.
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
Not applicable.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Issuer had one employee lay-off during the period. The length of the lay-off is indefinite as at the date of this report.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

On August 20, 2020 the Issuer announced the closing of a non-brokered private placement of unsecured convertible debentures.

Pursuant to the closing of the financing, the Issuer issued 500 convertible debentures at a price of \$1,000 per debenture for gross proceeds totalling \$500,000. Interest on the convertible debentures can be paid in either cash or common shares of the Issuer (at a deemed price per share equal to the conversion price, as such term is hereinafter defined), at the Issuer's election, at a rate of 7.5 per cent if paid in cash or 10 per cent if paid in common shares, payable semi-annually on the last day of June and December of each year, commencing on Dec. 31, 2020. The convertible debentures have a three-year term, with the principal amount being due to be repaid in full by the Issuer on Aug. 31, 2023.

In addition to the annual interest of 7.5 per cent or 10 per cent (as applicable), each initial holder of convertible debentures received a one-time commitment fee comprising 150 commitment warrants per convertible debenture. Each commitment warrant entitles its holder to acquire one common share at an exercise price of 55 cents per common share for a period of 24 months.

The Issuer has the right, at any time during the term, to repay in full the principal amount and any accrued and unpaid interest on the convertible debentures, provided that the Issuer gives 10 days of notice prior to doing so.

At any time during the term, a holder of convertible debentures may elect to convert the outstanding net principal amount, or any portion thereof, into units at a conversion price of 35 cents per unit. Each unit shall consist of one common share and one warrant, with each warrant entitling the holder to acquire a common share at an exercise price of 55 cents for a period ending on the maturity date.

The outstanding principal amount of each convertible debenture will automatically be converted into units at the conversion price (35 cents) if the common shares trade at a closing price of 75 cents or more on the Canadian Securities Exchange for 10 consecutive trading days. During the third year of the term, the Issuer shall have the option to extend the term by up to one additional year. If extended, then

the Issuer shall pay a cash extension fee to the holders of convertible debentures in the amount of six months of interest (at the rate of 7.5 per cent per annum).

The issuance of the convertible debentures and the commitment warrants was (and, if applicable, the units and any underlying common shares and warrants shall be) completed on a private placement and prospectus exempt basis, as applicable, such that the issuances are (or in the case of the units and any underlying common shares and warrants, shall be) exempt from any applicable prospectus and securities registration requirements.

Pursuant to National Instrument 45-102, Resale of Securities, all of the convertible debentures and commitment warrants issued pursuant to the financing (and any underlying units, common shares or warrants to be issued upon conversion or exchange of these securities) are subject to a four-month hold period, expiring on Dec. 21, 2020. Additional hold periods and/or trading or resale restrictions may also apply in the United States. In connection with the closing of the financing, an arm's-length finder received 112,000 finder warrants, with each finder warrant entitling the holder thereof to acquire one common share at a price of 35 cents per share for a period of 36 months from the date hereof.

Pursuant to the financing, a certain director of the Issuer subscribed for 10 convertible debentures for gross proceeds to the Issuer of \$10,000, which is considered a related party transaction within the meaning of Multilateral Instrument 61-101, Protection of Minority Securityholders in Special Transactions. Full details of this transaction will be available on SEDI. The financing is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the subject matter of the financing nor the consideration paid exceeds 25 per cent of the Issuer's market capitalization. No additional insiders or related parties of the Issuer participated in the financing or the debt settlement described as follows. No new insiders or control persons were created in connection with the closing of the financing. The financing was approved by all of the independent directors of the Issuer. The number of common shares potentially issuable to insiders of the Issuer pursuant to the financing (including any common shares issuable upon the conversion of the convertible debentures into units as well as the exercise of the commitment warrants and the warrants) represents not more than 10 per cent of the Issuer's currently issued and outstanding common shares on a non-diluted basis.

The Issuer intends to use the net proceeds of the financing for the deployment of its Affinity cannabis purification units as well as research into its AMIPs (accelerated molecularly imprinted polymers) virus detection technology.

The Issuer has settled \$60,000 of debt through the issuance of 60 convertible debentures with the same terms as the financing, as described herein.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Options	150,000	Option Grant	N/A
Warrants	75,000	Commitment Warrants on Convertible Debentures as described above (Section 13).	N/A
Warrants	112,000	Finder's Warrants as described above (Section 13).	N/A
Common Shares	614,994	Private Placement (as further described in Section 1).	As described in Section 1 above.

15. Provide details of any loans to or by Related Persons.

The Issuer has deferred salary loans with certain employees of the Issuer which accrue interest at 0.667% per month and will be repaid over 24 months at various payment amounts.

For further information respecting the deferred salary loans see the Issuer's Listing Statement dated February 6, 2020.

16. Provide details of any changes in directors, officers or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are outlined in the Issuer's Listing Statement dated February 6, 2020. The Issuer's Listing Statement is available on the Issuer's SEDAR profile at www.sedar.com and on the Issuer's disclosure with the CSE at www.thecse.com.

In March 2020 the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Issuer to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Issuer's business or results of operations at this time.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 7, 2020.

Peter Manuel
Name of Director or Senior
Officer

"Peter Manuel"
Signature
Director
Official Capacity

Issuer Details Name of Issuer Sixth Wave Innovations Inc.	For Month End: August 2020	Date of Report YY/MM/D 20/09/07
Issuer Address Suite 830-1100 Melville Street		
City/Province/Postal Code Vancouver, BC, V6E 4A6	Issuer Fax No. (902) 492-0197	Issuer Telephone No. 604-562-6915
Contact Name John Veltheer	Contact Position CFO	Contact Telephone No 604-562-6915
Contact Email Address jveltheer@sixthwave.com	Web Site Address www.sixthwave.com	